This expert discussion will provide optometrists with a comprehensive 30-minute education program on how to improve patient outcomes by managing ocular surface disease (OSD) in today’s optometric practice. The course will demonstrate the impact of the ocular surface on visual quality and review how to improve OSD diagnostic decisions. Program content will include a set of evidence-based didactic presentations, interactive discussions, and relevant case presentation discussions.
Supported by unrestricted educational grants from Alcon, Carl Zeiss Meditec, Inc., Glaukos, and Johnson & Johnson Vision.
Identify methods to improve surgical, and ocular surface and corneal disease outcomes through comanagement of cataract, refractive, and corneal patients
Describe the impact that OSD has on: Contact lens wear and drop out and Overall cataract and refractive surgery outcomes
Cite the incidence of OSD, dry eye flares, and MGD within the overall population
Compare and contrast traditional and new and emerging diagnostic tests in classifying ocular surface disease severity and differentiating MGD
This course is COPE approved for .5 hour of CE credit for optometrists.
Sponsored by State University of New York School of Optometry Office of Continuing Professional Education
Evolve is an approved COPE Administrator.
COPE Course ID: 67944-AS
COPE Event ID: #119404
Douglas K. Devries, OD
Co-Founder and Managing Partner
Eye Care Associates of Nevada
Marc Bloomenstein, OD, FAAO
Schwartz Laser Eye Center
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Douglas K. Devries, OD, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant and Speakers Bureau: Alcon, Bausch + Health, Bio Tissue, Dompe, EyeVance, Johnson & Johnson Vision, Lumeris, Novartis, OcuSoft, Sun, and TearLab, Share/Stockholder: RPS
Marc Bloomenstein, OD, FAAO, and/or spouse had a financial agreement or affiliation during the past year with the following commercial interest in the form of Consultant: Alcon, Allergan, Bausch + Lomb, Johnson & Johnson Vision, Novartis, OcuSOFT, Reichert and Sun. Speaker’s Bureau: Alcon, Allergan, Bausch + Lomb, Johnson & Johnson Vision, Novartis, and Sun. Research/Grant Support: Allergan. Stock/Shareholder: TearLab.
Editorial Support Disclosures
Erin K. Fletcher, MIT, director of compliance and education; Evolve; and Kate Fehlhaber, PhD, writer, have no financial relationships with commercial interests.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, Alcon, Carl Zeiss Meditec, Inc., Glaukos, and Johnson & Johnson Vision.